Elaris Takes Aim at Hospital Superbug with Next-Generation Vaccine Strategy

VIENNA, Austria – March 18, 2026 – In a significant move to combat one of the most persistent and deadly hospital-acquired infections, Austrian biotech firm Elaris announced today it has secured an exclusive global license from Valneva for a promising Clostridioides difficile (C. diff) vaccine program. The deal positions Elaris to advance a next-generation vaccine, aiming to succeed where other major pharmaceutical efforts have fallen short.

The agreement grants Elaris the rights to Valneva's antigen technology related to its C. diff vaccine candidate, VLA84. However, Elaris intends to do more than simply carry the torch. The company plans to integrate its own proprietary technology to create a differentiated vaccine designed to offer broader protection, reigniting hope in the long-running battle against this formidable pathogen.

The Silent Scourge of C. difficile

Clostridioides difficile, often called C. diff, is a toxin-producing bacterium that represents a severe public health crisis, particularly within hospitals and long-term care facilities. It is a leading cause of antibiotic-associated diarrhea, which can progress to life-threatening inflammation of the colon. According to the U.S. Centers for Disease Control and Prevention (CDC), the infection is responsible for nearly half a million infections and approximately 29,000 deaths annually in the United States alone. The burden is also immense in Europe, with an estimated 170,000 cases each year.

The infection typically preys on the vulnerable, including the elderly and immunocompromised, often taking hold after a course of antibiotics disrupts the protective bacteria in the gut. While treatments such as specific antibiotics or fecal microbiota transplants exist, they are not always effective, and recurrence rates are notoriously high. A significant portion of patients who recover from an initial episode will experience another, creating a vicious cycle of illness and hospitalization.

Despite this staggering impact, a critical gap remains in the medical arsenal: there is no approved prophylactic vaccine to prevent C. diff infection (CDI) in the first place. This unmet need has made the development of a successful vaccine a top priority for public health experts and a coveted goal within the pharmaceutical industry.

A Challenging Path to Prevention

The quest for a C. diff vaccine is littered with challenges and high-profile setbacks, underscoring the scientific difficulty of the task. For years, the primary strategy for vaccine developers has been to target the two main toxins produced by the bacterium, Toxin A and Toxin B, which are responsible for the disease's devastating symptoms.

Pharmaceutical giant Pfizer advanced its candidate, PF-06425090, into a large-scale Phase III clinical trial known as the CLOVER study. While the vaccine was found to be safe and did show some efficacy in reducing the severity and duration of the illness, it ultimately failed to meet its primary endpoint of preventing the initial onset of C. diff infection. Another major player, Sanofi, halted the development of its own C. diff vaccine candidate in 2017 after a mid-trial analysis suggested it was unlikely to meet its primary objective.

These near-misses have highlighted the limitations of a purely toxin-focused approach. Experts have noted that while neutralizing toxins can prevent a patient from getting sick, it may not prevent them from becoming colonized with the bacteria, potentially allowing them to still carry and transmit it. This complex reality has pushed researchers to explore more comprehensive strategies.

Elaris's Next-Generation 'Dual Mode' Strategy

Enter Elaris, a company founded with the mission of protecting vulnerable populations from serious bacterial diseases. The licensing of Valneva's VLA84, a candidate that had already demonstrated a good safety profile and immune response in Phase II trials, provides Elaris with a solid foundation. But the company's true innovation lies in what it plans to add.

Elaris is advancing what it calls a "Dual Mode Vaccine Approach." The first mode of action, leveraging the licensed technology, involves neutralizing the disease-causing toxins to prevent illness. The second, and potentially game-changing, mode involves incorporating additional proprietary components designed to target the bacterium itself, aiming to prevent or reduce colonization in the gut. By preventing the bacteria from gaining a foothold, this dual-action strategy could not only stop the disease but also reduce infection, recurrence, and transmission—a significant step beyond previous vaccine candidates.

"Securing this license represents an important step toward our goal of preventing serious bacterial infections that disproportionately affect aging and vulnerable populations," said Jason Golan, Chief Executive Officer and Co-Founder of Elaris, in the company's press release. "By building on Valneva's antigen technology with additional proprietary components, we aim to develop a differentiated vaccine designed to broaden protection against C. difficile infection."

A Strategic Partnership for the Future

For Valneva, a commercial-stage vaccine company with products for Chikungunya and Japanese encephalitis, the deal represents a strategic move to maximize the value of its pipeline. By partnering with a specialized company like Elaris, Valneva can see its VLA84 program advance while focusing its internal resources on other key assets, such as its Lyme disease vaccine candidate currently in Phase III trials. The agreement includes potential development, regulatory, and commercial milestone payments, as well as royalties on future sales, ensuring Valneva retains a financial stake in the program's success.

"CDI continues to pose a significant public health challenge," noted Thomas Lingelbach, Chief Executive Officer of Valneva. "We are pleased to partner with Elaris to advance this technology and look forward to seeing the program progress as Elaris continues development."

Elaris now faces the rigorous and costly process of advancing the program through the final stages of preclinical development required for an Investigational New Drug (IND) application. The company is targeting the initiation of clinical studies around 2027. The road ahead is long, but if Elaris's dual-action strategy proves successful in clinical trials, it could deliver the world's first approved vaccine against C. diff. Such a breakthrough would not only save thousands of lives but also reduce hospital stays, curb antibiotic use, and mark a major victory in the global fight against antimicrobial resistance. The medical community will be watching closely to see if this new strategy can finally deliver a much-needed shield against a relentless bacterial threat.